Related Experiment Video
Updated: Feb 10, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Contemporary Approaches to In-Transit Melanoma
Jennifer A Perone1, Nellie Farrow1, Douglas S Tyler1
1University Texas Medical Branch, Galveston, TX; and Duke University, Durham, NC.
Abstract:
In-transit melanoma represents a distinct disease pattern of heterogeneous superficial tumors. Many treatments have been developed specifically for this type of disease, including regional chemotherapy and a variety of directly injectable agents. Novel strategies include the intralesional delivery of oncolytic viruses and immunocytokines. The combination of intralesional or regional chemotherapy with systemic immune checkpoint inhibitors also is a promising approach. In the current review, we examine the general management of the workup of patients with in-transit disease, the range of available therapies, and recommendations for specific therapies for an individual patient.
Insights
This review covers in-transit melanoma treatments, including regional chemotherapy, injectable agents, oncolytic viruses, and immune checkpoint inhibitors. It offers guidance on patient workup and personalized therapy recommendations for this distinct cancer pattern.
Area of Science:
- Oncology
- Dermatology
- Cancer Research
Background:
- In-transit melanoma is a specific pattern of superficial, heterogeneous tumors.
- Various treatments exist, including regional chemotherapy and injectable agents.
- Emerging strategies involve intralesional oncolytic viruses and immunocytokines.
Purpose of the Study:
- To review the management of patients with in-transit melanoma.
- To outline the spectrum of available therapeutic options.
- To provide recommendations for individualized treatment strategies.
Main Methods:
- Review of current literature on in-transit melanoma management.
- Analysis of established and novel therapeutic approaches.
- Synthesis of data to inform clinical decision-making.
Main Results:
- In-transit melanoma requires specific management approaches.
- Regional chemotherapy and injectable agents are established treatments.
- Combination therapies, including immune checkpoint inhibitors, show promise.
Conclusions:
- Personalized treatment selection is crucial for in-transit melanoma.
- A combination of local and systemic therapies may offer optimal outcomes.
- Ongoing research is vital for advancing treatment paradigms.
Related Concept Videos
Contemporary Psychology
Biopsychology
Biopsychology, also known as biological psychology or behavioral neuroscience, focuses on the biological underpinnings of behavior and mental processes. It...
Phase Transitions
Properties of Transition Metals
Cooperative Allosteric Transitions
Cooperative Allosteric Transitions
Phase Transitions: Vaporization and Condensation

